The Supernus event will provide an overview of the Company’s pipeline, with emphasis on SPN-820/821, SPN-817 and new clinical candidates from the Company’s discovery program. In addition, a key opinion leader will share his perspectives on the current treatment paradigms, unmet medical needs and the Company's clinical development programs.
President and Chief Executive Officer, Director
Chief Medical Officer Research & Development
Vladimir Maletic, M.D., MS
Clinical professor, Neuropsychiatry and Behavioral Science